Heptares moves to Welwyn BioPark and plans further expansion
Heptares’ CEO, Dr Malcolm Weir, said: “Heptares has progressed rapidly since 2007, and the new funds we raised earlier this year have given us a very good opportunity to implement our strategy for generating new drug candidates to highly validated but previously challenging GPCRs. We are pleased to move to the Welwyn BioPark, which provides a first-class research environment within easy reach of London and Cambridge, where we retain excellent scientific links.”
The Company’s new address as from 12 May 2008 is:
Heptares Therapeutics Ltd, BioPark, Broadwater Road, Welwyn Garden City, Hertfordshire, AL7 3AX
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.